The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed ...

Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex ...

The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority review on a key drug and Third Harmonic restructured.

With this acquisition, LipoVation becomes a wholly owned subsidiary of Revium Rx, aligning with the company’s renewed commitment to drug delivery innovation. Revium Rx is developing a portfolio of ...

From preclinical research to regulatory approval and clinical adoption, diagnostic testing underpins every stage of ADC ...

In what one analyst called a “unique situation,” the company stopped dosing patients on the recommendation of trial monitors, ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

CagriSema, which underperformed expectations in its first Phase 3 test, will be studied at different doses and for longer ...

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...

Shares in the brain drug developer rose by more than 20% Monday on news of the deal, which will forestall Teva's generic copy of Auvelity from entering the U.S. market until at least 2038.

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a hangup for insurers and limit ...

The pharmaceutical company plans to cut $2 billion in annual expenses by the end of 2027 through “operational efficiencies ...